Statistics from Altmetric.com
In Chile, the guaranteed therapy for rheumatoid arthritis did not consider biological drugs until 2015, when Law 20850 was promulgated.1 The criteria to start biological treatment and the follow-up periods differ from validated treat to target (T2T) strategies,2 allowing access only to patients who remain with a disease activity Score-28 with erythrocite sedimentation rate (DAS28-ESR) >5.1 despite 6 months of treatment with three non-biological disease-modifying antirheumatic drugs (DMARDs).3 Our results of the application of this law during the first year were recently published.4
The implementation of this law allowed us to identify difficulties to implement a successful T2T strategy: (1) access to the rheumatologist; (2) impossibility of carrying out an early control because of absence of medical hours; (3) limitation in the therapeutic …
Handling editor Josef S Smolen
Contributors All the authors made substantial contributions to the conception and design of the work.
Competing interests None declared.
Patient consent Not required.
Ethics approval Comité de evaluación ético científico del servicio de salud metropolitano oriente.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.